Dublin, Aug. 10, 2016 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Autoimmune Haemolytic Anemia Forecast in 8 Major Markets 2016-2026" report to their offering. Autoimmune haemolytic anaemia (AIHA) is an immune disorder caused by auto-antibodies against unmodified autologous red blood cells and can range in presentation from a mild illness to a rapidly fatal severe condition. This report provides the current incident population for AIHA across 8 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil and Japan) split by gender and 5-year age cohort. Along with the current incidence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity. Providing a value-added level of insight from the analysis team, several of the main symptoms and co-morbidities of AIHA's have been quantified and presented alongside the overall incidence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot. Main symptoms and co-morbidities for AIHA include: - Lymphoproliferative conditions: - - CLL - - HL - - NHL - Myeloproliferative conditions: - - Multiple myeloma - - Myelofibrosis - - MGUS - Autoimmune conditions: - - RA - - SLE - - Polyarteritis nodosa - Infections: - - Pneumonia & Tuberculosis - - Syphilis - - Epstein-Barr - - Chronic active hepatitis - - Mononucleosis Reasons to Buy: - Able to quantify patient populations in global AIHA's market to target the development of future products, pricing strategies and launch plans. - Gain further insight into the incidence of the subdivided types of AIHA and identify patient segments with high potential. - Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries. - Provide a level of understanding on the impact from specific co-morbid conditions on AIHA's incident population. - Identify sub-populations within AIHA which require treatment. - Gain an understanding of the specific markets that have the largest number of AIHA patients. Key Topics Covered: 1. List of Tables and Figures 2. Introduction 3. Cause of the Disease 4. Risk Factors & Prevention 5. Diagnosis of the Disease 6. Variation by Geography/Ethnicity 7. Disease Prognosis & Clinical Course 8. Clinical Management of AIHA - Transfusion therapy in AIHA 9. Key Co-morbid Conditions/Features Associated with the Disease 10. Methodology for Quantification of Patient Numbers 11. Top-Line Incidence for AIHA 12 Subtypes of AIHA patients - Warm AIHA patients - Cold AIHA patients - Mixed-type AIHA patients 13. Market Forecast for AIHA - 1st Line Treatment Options within Warm & Mixed-type AIHA - 2nd Line Treatment Options within Warm & Mixed-type AIHA - 1st Line Treatment Options within Cold AIHA - 2nd Line Treatment Options within Cold AIHA - Requirement for Blood Transfusions within AIHA 14. Methodology for Forecast Figures 15. Abbreviations used in the report 16. Patient-Based Offering 17. Online Pricing Data and Platforms 18. References 19. Appendix For more information visit http://www.researchandmarkets.com/research/c755wk/autoimmune
CONTACT: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Sector: Hematology
